Novel Neuroimage Study in Tauopathies With Parkinsonism

Status Completed

Clinical Trial Summary

The aims of this study are: 18F-THK5351 PET(Positron Emission Tomography) can defect the tau burden in PSP(Progressive Supranuclear Palsy) and CBS (Corticobasal syndrome)correlating with the known NFT(neurofibrillary tangles) topology of those diseases, 18F-THK5351 PET will differentiate subjects with suspected tauopathy due to PSP and CBS from subjects with suspected synucleinopathy due to idiopathic PD(Parkinson's disease). The distribution of PHF(paired helical filament) tau burden will correlate with specific motor and cognitive features of PSP and CBS; and regional PHF tau burden will be associated with cortical thinning. Together, these efforts will establish the potential for developing 18F-THK5351 PET imaging as a biomarker and diagnostic tool for the parkinsonian tauopathies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03386669
Study type	Interventional
Source	Chang Gung Memorial Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	July 31, 2017
Completion date	July 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02194816` - Modifiable Variables in Parkinsonism (MVP)
Recruiting	`NCT04876326` - Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy	N/A
Active, not recruiting	`NCT05127057` - Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT)	N/A
Enrolling by invitation	`NCT01453127` - DaTSCAN Imaging in Aging and Neurodegenerative Disease	Phase 4
Completed	`NCT01174771` - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration	N/A
Completed	`NCT03314610` - Effect of Need to Void on Parkinsonian Gait
Recruiting	`NCT05506891` - Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy	Phase 2
Completed	`NCT00950196` - Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia	Phase 4
Recruiting	`NCT03924414` - Trial of Parkinson's And Zoledronic Acid	Phase 4
Enrolling by invitation	`NCT05514106` - MIBG in Aging and Neurologic Disorders	Phase 4
Completed	`NCT01581645` - Mobilaser Study to Help With People Who Are Having Problems With Their Gait	Phase 0
Not yet recruiting	`NCT00767546` - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients	Phase 1
Completed	`NCT02214862` - 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism	Phase 0
Recruiting	`NCT04518059` - Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
Completed	`NCT03076671` - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease	N/A
Withdrawn	`NCT01329926` - Molecular Analysis of Human Neural Stem Cells
Terminated	`NCT00745030` - Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism	N/A
Completed	`NCT04222218` - Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy	N/A
Completed	`NCT02064543` - Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism
Active, not recruiting	`NCT05308485` - Events Exposure as a Trigger of the Clinical Manifestations of Parkinson's Disease